



## **MEDICREA Announces U.S. Launch of New Generation LigaPASS® Band System for Spinal Posterior Fixation**

*Latest Generation Includes Improved Surgical Capabilities and Expanded FDA Indications*

**NEW YORK, NY and LYON, France (April 30, 2015)** – The [MEDICREA Group](#) (Alternext Paris: FR0004178572 - ALMED), a company that specializes in the development of innovative spinal implants for the treatment of spinal pathologies, today announced the U.S. launch of [LigaPASS® 2.0 generation](#), MEDICREA’s band connector technology for posterior thoraco-lumbar fixation. The next-generation technology features numerous improvements and is now cleared for use in adolescent idiopathic and neuromuscular scoliosis patients 10 years of age and older in addition to adults.

With over 5,000 LigaPASS® systems implanted worldwide in the past two years, MEDICREA’s proprietary technology provides surgeons with a safe and efficient alternative solution to screws and hooks that allows translation and derotation of vertebral bodies. The new generation system features an extended range of connectors, a band with a narrower malleable tip to allow for safer passage underneath the lamina and a dual-band option, which allows surgeons to pass two bands underneath the lamina at once, saving considerable time during neuromuscular cases.

“The LigaPASS® which is the only sub-laminar band technology truly offering de-rotation capabilities, has become an integral part of my surgical treatment for adolescent idiopathic scoliosis (AIS) patients,” said Afshin Aminian, M.D., a pediatric orthopedic surgeon and medical director at Children’s Hospital of Orange County, USA. “I’ve been using it for over three years and the clinical outcomes have been excellent. Through improved features such as the thinner malleable tip and dual-band option, this latest version offers even greater capabilities and ease of use to meet my needs in the OR, and will allow surgeons to provide optimal care to their patients.”

The LigaPASS® 2.0 generation is universal. Every connector can be used with the most common rod diameters available on the market (from 5.5 to 6mm). The range now includes 2 new connectors: the LigaPASS® LP and the LigaPASS® Open. With its extra-low profile design, the LigaPASS® LP Connector offers greater capabilities for operating on very difficult neuromuscular cases and young, small patients. LigaPASS® Open is an open connector that can be inserted onto the rod of an already existing construct, offering placement versatility at any stage during the surgery.

“For small osteopenic neuromuscular scoliosis patients, LigaPASS® 2.0 provides an excellent alternative to pedicle screws without compromising fixation,” said Samuel R. Rosenfeld, M.D., a pediatric orthopedic surgeon and director of the Spina Bifida Clinic, Muscular Dystrophy Clinic and Spasticity Clinics at Children’s Hospital of Orange County, USA. “With version 2.0, MEDICREA has taken this band technology to another level, not only by improving the design and performance, but also by creating a full range of LigaPASS® components that can address any AIS or neuromuscular case.”

Denys SOURNAC, Founder, CEO and Chairman of MEDICREA, added, “We are extremely pleased with the growing rate of LigaPASS® use among surgeons and the excellent outcomes patients have experienced during more than three years of adoption. As part of our commitment to improving outcomes for patients



and offering our customers groundbreaking innovation to make their jobs more efficient, we believe we have reinvented the concept of ‘band-connectors’ and developed implants and instruments that dramatically improve ease of use and functionality”.

#### **About MEDICREA ([www.medicrea.com](http://www.medicrea.com))**

The MEDICREA Group is dedicated to providing neurosurgeons and orthopedic spine surgeons with new and less-invasive surgical solutions that are faster and easier to implement than traditional techniques, especially in the field of complex surgeries requiring sagittal alignment.

The company is also the pioneer and the global leader in the design, manufacture, and distribution of innovative proprietary technologies devoted to patient-specific spinal surgery. MEDICREA’s products support better patient care and improved economic outcomes by offering revolutionary technologies that are customized for each individual patient. The Group offers UNiD™ Rod, the world’s first patient-specific spinal osteosynthesis rod, through a comprehensive process incorporating software analysis of each patient, pre-surgical planning of the surgical strategy, and the seamless production of patient-specific pre-contoured rods. MEDICREA’s innovative UNiD™ patient specific technology platform also includes interbody fusion devices and corpectomy morpho-adjusted cages very precisely manufactured with a 3-D printer from a specific digitalization process of each patient scanner images.

Operating in a \$10 billion market, MEDICREA is a small to medium-sized business having achieved 24,1 €M sales in 2014, with 140 employees, including 40 at its MEDICREA USA Corp. subsidiary based in New York City. The Group’s headquarters are located near Lyon, France. The company owns its integrated implant and surgical instrument manufacturing facility based in La Rochelle, France, as well as three distribution subsidiaries with their own direct salesforce in the U.S., the U.K. and France.

#### **Contacts:**

##### **MEDICREA**

Denys Sournac, Founder, Chairman and CEO

[dsournac@medicrea.com](mailto:dsournac@medicrea.com)

Fabrice Kilfiger, Chief Financial Officer

[fkilfiger@medicrea.com](mailto:fkilfiger@medicrea.com)

Tel: +33 (0)4 72 01 87 87

##### **NewCap.**

Financial Communication / Investor & Press Relations

Sophie Boulila / Pierre Laurent

Tel: +33 (0)1 44 71 94 91

[medicrea@newcap.fr](mailto:medicrea@newcap.fr)

##### **MEDIA**

Brian Baxter for MEDICREA

[bbaxter@lazarpartners.com](mailto:bbaxter@lazarpartners.com)

Tel: +1 646-871-8491



**MEDICREA is listed on ALTERNEXT Paris**

**ISIN: FR 0004178572 – Ticker: ALMED**